Kornimate/medical-research-clean huggingface dataset:
application of ultrasound-guided thoracic paravertebral block in pulmonary ablation surgery

Conditions: Lung Cancer

Summary: local thermal ablation therapy of tumor is a rapidly developing minimally invasive therapy for lung tumors in recent years. this study evaluated the efficacy of thoracic paravertebral block (tpvb) for anaesthesia during ablation surgery of lung tumor.

lung cancer is a serious threat to human health and life. local thermal ablation therapy of tumor is the focus of domestic and overseas research in the past decade.thoracic paravertebral nerve block (tpvb) is the technique of injecting local anaesthetic in the paravertebral space to anesthetizes the spinal nerve roots and sympathetic chain，which will produces ipsilateral and somatic blockade.the present study was designed to evaluate the analgesic effect and safety of tpvb in the ablation surgery of lung tumor. after obtaining approval from the hospital ethics committee and informed written consent from the patients,30 adult patients scheduled for local thermal ablation therapy of lung tumours were recruited. patients were excluded if they had a history of psychiatric illness, chronic pain, regular analgesic usage or there were contraindications to performing a tpvb, such as chest wall deformity, severe coagulopathy, local infection and allergy to local anaesthetic drugs. the study lasted a total of six months. during the preoperative visit, all patients received the explanation of overall research approach.after entering the ct fluoroscopy room, peripheral veins and routine monitoring that included electrocardiography, pulse oximetry, and noninvasive arterial blood pressure were obtained in all patients.thoracic paravertebral block was performed 20 minutes before the local thermal ablation therapy began.the degree of pain was assessed using vas score; at performing tpvb，the beginning of surgery， 6 and 24 hours after ablation surgery.dezocine will be given as remedial analgesia.following the operation, transferred the patients to the observation area where the vital signs were monitored for 30 min.assessing and record the degree of patients and surgeons satisfaction for anesthetic management.

Eligibility criteria:
inclusion criteria 1. patients diagnosed with lung cancer by imaging examination 2. informed consent of the patient and study approval by the medical ethics committee exclusion criteria 1. have a history of psychiatric illness, chronic pain, regular analgesic usage 2. have contraindications to performing a tpvb, such as chest wall deformity, severe coagulopathy, local infection 3. have allergy to local anaesthetic drugs
exercise intolerance in obstructive sleep apnea syndrome patients

Conditions: Obstructive Sleep Apnea

Summary: the syndrome of obstructive sleep apnea (osas) is a public health problem that affects 2 to 4% of the general population. the patients with osas frequently complain of intolerance to exercise muscle fatigue and a significant even if they have not been fully characterized in the literature. the anomalies in the exercise of patients with osas could be due to metabolic changes (insulin resistance and oxidative stress) and cardiovascular (impaired vascular reactivity). our goal is both to determine whether these anomalies exist in patients with osas not obese, consider their relationship with the alteration of exercise capacity, and their reversibility in conventional ppc or by using the effects of physical activity regular.in this study objectives: to establish whether the metabolic and vascular abnormalities associated with osas are associated with decreased parameters of physical fitness in relation to witnesses matched for age, sex and body mass index. determine the effects of a re-training exercise on these parameters compared to the reference treatment, continuous positive pressure. main objective: to compare the exercise capacity of osas patients compared with that of witnesses matched for age, sex and body mass index. secondary objectives: to compare the effect of conventional treatment by continuous positive pressure (cpp) on cardiovascular and metabolic abnormalities of osas, with a therapeutic modality most original, physical activity. methodology: test physiopathological parallel group, controlled, randomized.

study type : physiopathology trial study design : prospective randomized controled trial expected total enrollment : 45 patients + 15 control subjects tested treatment : physical exercise program (45 minutes, 3 times a week) reference treatment : continuous positive airway pressure treatment duration : 12 weeks (3 months) total study duration : 2 years

Eligibility criteria:
inclusion criteria: * ages eligible for study : 18 years and above * genders eligible for study: both * non obese : body mass index (bmi \< 30 kg/m2) * sedentary subjects : less physical activity than 30 minutes 3 time a week * and voorips physical activity level questionnaire score \< 9. obstructive sleep apnea syndrome (osas) patients : * recently diagnosed (\< 3 months) * ahi \> 30 / hour (polysomnographic monitoring measurement) exclusion criteria: * excessive daytime sleepiness (epworth score \> 12) * cardiovascular pathology (except controlled hypertension) * pathology interacting with physical activity * diabetes (known or treated) * other participation to a clinical trial at the same

Keywords: osas exercise metabolic cardio-vascular
encourage: evaluating community peer advisors and diabetes outcomes in rural alabama

Conditions: Diabetes Mellitus

Summary: it is unclear whether peer coaching is effective in minority populations living with diabetes in hard-to-reach, under resourced areas such as the rural south. we examined the effect of an innovative peer coaching intervention plus brief education vs. brief education alone on diabetes outcomes.

the purpose of this project was to provide robust evidence on the effectiveness of a peer support intervention in improving diabetes outcomes by conducting a group-randomized, controlled implementation trial of a volunteer peer support intervention. the study had three specific aims: aim 1. in phase i (months 0-8), to perform a qualitative needs assessment with peer advisors and health care providers to inform peer advisor roles and responsibilities (i.e., the intervention) and peer advisor recruitment strategies, curriculum and training; and patient recruitment plans. aim 2. also in phase i, to pilot our collaboratively developed intervention and, based on pilot test results, to recruit and train peer advisors for the intervention, and begin patient recruitment. aim 3. in phase ii (months 9-32), conduct the group randomized implementation trial and evaluate it using the reach, effectiveness, adoption, implementation, maintenance (re-aim) framework.

Eligibility criteria:
inclusion criteria: * 19 or older in age, diagnosed with diabetes, under the care of a doctor exclusion criteria: * not community dwelling, less than 19 years old, pregnant, end-stage medical conditions with limited life expectancy, no access to telephone, does not speak english

Keywords: diabetes mellitus peer support pragmatic clinical trial
multi-center clinical research of acupuncture treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: knee osteoarthritis (koa) is a major public health problem among the elderly and is associated with considerable disability. a recent analysis of data indicated that about 35% of women and men aged 60 years and above had radiographic knee oa.despite the high prevalence rate of oa, the treatment of oa is far from satisfactory. acupuncture may be a promising treatment option for knee oa due to the effectiveness of the pain relief and the rarity of adverse effects. in order to get some more reliable data to confirm acupuncture effectiveness on koa, a long-term follow up interventional study will be started to confirm the effects of long term for acupuncture treatment.

knee osteoarthritis (koa) is a major public health problem among the elderly and is associated with considerable disability. a recent analysis of data from the national health and nutrition examination survey iii indicated that about 35% of women and men aged 60 years and above had radiographic knee oa. although the cause of oa can be many factors, such as previous injury, abnormal limb development and so on, its main symptom is a complex chronic pain condition. previous studies have demonstrated central sensitization in oa patients. despite the high prevalence rate of oa, the treatment of oa is far from satisfactory. acupuncture could be a promising treatment option for knee oa due to the effectiveness of the pain relief and the rarity of adverse effects. in order to get some more reliable data to confirm acupuncture effectiveness on koa, a long-term follow up interventional study with clear design, standard criteria, control group, will be started to confirm the effects of long term for acupuncture treatment.

Eligibility criteria:
inclusion criteria: * male and female patients who have knee oa diagnosed according to the american college of rheumatology classification criteria (with at least one osteophyte in the tibiofemoral joint and with a kellgren-lawrence grade of more than 2). * male and female patients who have had a history of moderate or greater knee pain of more than 3 months' duration and have reported moderate or greater, clinically significant, knee pain during most days of the last month before the interview. * male and female patients who have given their consent to participate in the study. * patients will be selected among those who are not on the waiting list for total knee arthroplasty by the traumatology unit of our hospital. exclusion criteria: * patients with any of the following will be excluded from the study: a history of any secondary oa associated with any systemic arthropathy (i.e., rheumatoid arthritis or gouty arthritis); * any knee treatment with steroids, methotrexate, or azathioprine; recent traumatisms caused by acupunctured insertion; * a history of bleeding disorders or any disease related to acupuncture contraindications; * a history of any knee injection in the previous 6 months (e.g., cortisone and hyaluronic acid); a history of morphine or morphine derivative use.
a study to evaluate the efficacy, safety and tolerability of fixed doses of intranasal esketamine in japanese participants with treatment resistant depression

Conditions: Depression

Summary: the purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in japanese participants with treatment-resistant depression (trd), in improving depressive symptoms.


Eligibility criteria:
inclusion criteria: * at the start of the screening phase, participant must meet the diagnostic and statistical manual of mental disorders (dsm-5) diagnostic criteria for single-episode major depressive disorder (mdd) or recurrent major depressive disorder (mdd), without psychotic features, based upon clinical assessment and confirmed by the mini international neuropsychiatric interview (mini). in the case of single-episode mdd, the participant must be diagnosed with persistent depressive disorder, which meets criteria of major depressive episode for a continuous duration of greater than or equal to (\>=)2 years, and the same physician from the site must be examining the participant for \>=2 years continuously as a primary care physician of the participant * the participant's current major depressive episode, depression symptom severity (madrs total score greater than or equal to \[\>=\] 28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using the safer interview * participant must be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs (including blood pressure), pulse oximetry, and 12-lead electrocardiogram (ecg) performed in the screening phase * a woman of childbearing potential must have a negative highly sensitive serum beta (β) human chorionic gonadotropin \[β-hcg\] test at the start of the screening phase and a negative urine pregnancy test must be obtained before the first dose of study drug on day 1 of the double-blind induction phase prior to randomization * contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies exclusion criteria: * participant has received vagal nerve stimulation or has received deep brain stimulation in the current episode of depression * participant previously received esketamine or ketamine as treatment for their mdd * participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase * participant has a history of moderate or severe substance or alcohol use disorder according to dsm-5 criteria, except nicotine or caffeine, within 6 months before the start of the screening phase * participant has a current or past history of seizure disorder (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
photodynamic therapy in anal fistula

Conditions: Rectal Fistula

Summary: objective: validate and analyze the results of intralesional photodynamic therapy in the treatment of complex anal fistula. methods: prospective observational study including patients treated for complex anal fistula who underwent intralesional photodynamic therapy (i-pdt). patients were included with a minimum follow up of 1-year, in order to evaluate recurrence, continence and postoperative morbidity. intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. the internal and external orifices were closed. after an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (multidiode 630 pdt, intermedic, spain) operating at 1 w/ cm for 3 min (180 joules).


Eligibility criteria:
inclusion criteria: * complex anal fistula according to parks classification exclusion criteria: * non cryptoglandular fistulas * acute sepsis * inflammatory bowel diseases * simple fistulas (defined as subcutaneous, intersphincteric and low transsphincteric fistula) * pregnant patients * asa iv * patients \<18 * immunocompromised * patients who refused consent.
a study of tadalafil after radical prostatectomy

Conditions: Erectile Dysfunction

Summary: the study will include patients with localized prostate cancer who experience erectile dysfunction following bilateral nerve-sparing radical prostatectomy. patients will be randomly assigned to three treatment arms: tadalafil 5 mg once a day, tadalafil 20 mg on demand (prior to anticipated sexual activity), and placebo. patients will stay on therapy for 9 months and after withdrawal of medication for 6 weeks, patients will be evaluated for recovery of unassisted erectile function (without medication). an open-label extension for three months will evaluate the responsiveness of all patients to tadalafil 5 mg once a day. further objectives are to evaluate the treatment satisfaction of the respective therapies.


Eligibility criteria:
inclusion criteria: * scheduled to undergo bilateral nerve-sparing radical prostatectomy (bnsrp) for organ-confined, non-metastatic prostate cancer * have a normal preoperative erectile function score of more or equal to 22 at screening(as evaluated by international index of erectile function - erectile function domain (iief-ef)) * develop erectile dysfunction (ed) (defined as the consistent inability to achieve and/or maintain an erection sufficient to permit satisfactory sexual intercourse) after surgery * have an interest in resuming sexual activity as soon as possible after surgery and anticipate having the same adult female sexual partner during the study * agree not to use any other treatment for ed, including herbal and over-the-counter (otc) medications, during the study * does not require the initiation of adjuvant therapy for prostate cancer exclusion criteria: * history of ed * have received previous or current treatment with tadalafil or any other phosphodiesterase type 5 (pde5) inhibitor * have undergone, or plan to undergo, radiation or hormonal therapy for prostate cancer * have a history of prostatic surgery or prostatic physical treatments * have a history of diabetes mellitus * have a history of galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption * have clinically significant renal insufficiency as determined by the investigator

Keywords: erectile dysfunction radical prostatectomy
docetaxel and ptk787 in metastatic breast cancer patients and gynecological cancer patients

Conditions: Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Breast Cancer

Summary: the main purpose of this study is to see if the study drug, ptk787, is safe and to find the highest dose that can be given safely without causing serious side effects.

* patients will come to the clinic once a week to receive study treatment. to help reduce the chance of an allergic reaction patients will take decadron tablets orally the night before, the morning of and the evening of receiving chemotherapy. * the lead-in schedule of dosing is as follows: day 1: taxotere intravenously; day 4: ptk787 orally; day 14: taxotere and ptk787. * after the lead-in schedule, a cycle will consist of 28 days. ptk787 will be given orally once a day without interruption. taxotere will be given on day 1, day 8, day 15 and day 22. * before each dose of taxotere, blood tests, urine tests, and a physical exam will be done. a radiological evaluation will be done every two months. if the patients tumor remains stable or shrinks in size, they may continue to stay on the study. * patients should not eat grapefruit or drink grapefruit juice during this study.

Eligibility criteria:
inclusion criteria: * recurrent gynecological cancers or metastatic breast cancer. initial diagnosis must be confirmed histologically. * measurable disease or nonmeasurable disease * age \> 18 years * ecog performance 0,1,2 * 4 weeks or greater since major surgery, 3 weeks or greater since chemotherapy * certain lab values * negative for proteinuria exclusion criteria: * four or more treatment regimens * history or presence of uncontrolled cns disease * prior biologic or immunotherapies less than 3 weeks prior to registration * prior full field radiotherapy less than 4 weeks or limited field radiotherapy less than 2 weeks prior to registration * prior therapy with anti-vegf agents * peripheral neuropathy with functional impairment \> ctc grade 2 * pregnant or breast feeding * concurrent severe and/or uncontrolled medical condition * chronic renal disease * acute or chronic liver disease * impairment of gastrointestinal function or gi disease * confirmed diagnosis of hiv infection are excluded at the investigators discretion * therapeutic warfarin sodium or similar oral anticoagulants that are metabolized by the cytochrome p450 system.

Keywords: ptk787 metastatic breast cancer refractory gynecological cancer
wei nasal jet for the sedation of outpatient upper gastrointestinal endoscopy

Conditions: Peptic Ulcer; Gastric Cancer; Esophagus Cancer; Oesophagitis; Hypoxia

Summary: low pulse oximetry is the most common adverse events during sedation for upper gastrointestinal endoscopy. the main reason is the glossoptosis after sedation. in present study a new designed nasopharyngeal airway embedded with jet ventilation catheter(wei nasal jet) will be utilized in order to reduce the hypoxia. at the same time the safety will be evaluated.


Eligibility criteria:
inclusion criteria: * patients undergoing upper gastrointestinal endoscopy * age over 18 years old * signed informed consent form exclusion criteria: * a blood coagulation dysfunction or have a tendency of nose bleeding * a clear diagnosis of heart disease (heart failure, angina, myocardial infarction, arrhythmia, etc.) * a clear diagnosis of lung disease (asthma, chronic obstructive pulmonary disease, pulmonary embolism, pulmonary edema, lung cancer) * pregnant * liver disease * kidney disease * increase in intracranial pressure * emergency operation * multiple trauma * american society of anesthesiologists (asa) physical status classification above iv * with mouth, nose and throat infection

Keywords: sedation low pulse oximetry upper gastrointestinal endoscopy wei nasal jet
china s3: safety and effectiveness of edwards lifesciences sapien 3 thv in the chinese population

Conditions: Aortic Stenosis; Symptomatic Aortic Stenosis; Aortic Regurgitation

Summary: to evaluate the safety and effectiveness of the sapien 3 (edwards lifesciences, irvine, california) transcatheter heart valve implantation (tavi) in chinese patients with symptomatic severe calcific aortic stenosis who are considered at high risk for surgical valve replacement.

edwards sapien 3 transcatheter heart valve and commander delivery system will be used for this study. a maximum of 60 patients with symptomatic severe calcific aortic stenosis requiring transcatheter aortic valve implantation (tavi), who are considered high risk for surgical valve replacement who received a sapien 3 thv.

Eligibility criteria:
inclusion criteria: 1. subjects who are considered to be operable and high risk for surgical valve replacement: sts score ≥ 8 and ≤ 15 or logistic euroscore ≥ 15 and ≤ 40. if sts score is below 8 and logistic euroscore is below 15, patients should have other clinical or anatomical risk factors that would be considered high risk for surgery and documented by the heart team. 2. severe symptomatic aortic stenosis requiring aortic valve replacement characterized by one or more of the following within 60 days prior to the index procedure: ava \ 40mmhg, or peak aortic jet velocity \> 4.0m/sec. 3. nyha functional class ii or greater. 4. the study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ec of the respective clinical site. 5. the study patient agrees to comply with all required postprocedure follow-up visits. exclusion criteria: 1. evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment. 2. aortic valve is a congenital unicuspid or is non-calcified. 3. aortic valve is bicuspid and the patient is less than 60 years old, or the aortic valve is bicuspid with no raphe (sievers classification type 0). 4. anomalous coronary artery that would interfere with proper placement of the valve. 5. mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation \>3+).

Keywords: tavi tavr china sapien 3 high risk transcatheter aortic valve implantation transcatheter aortic valve replacement